New Long-Acting growth hormone shot could mean fewer needles for kids
NCT ID NCT07450001
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new medicine called GenSci134, a long-acting growth hormone, in 128 children with growth hormone deficiency (GHD). The goal is to find the best dose and see if it is safe and helps children grow taller. In the first part, children get one shot of GenSci134; in the second part, they get weekly shots for 24 weeks and are compared to children taking a daily growth hormone (Norditropin). The study is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GenSci134 (a long-acting growth hormone injection)
- What this could lead to
- If it works, this could provide a more convenient treatment option for children with growth hormone deficiency, potentially requiring fewer injections than current daily hormone shots.
- What could go wrong
- This is an early-phase trial (phase 1b/2) with only 128 children, so it is too soon to know if GenSci134 is safe or effective. The study is not yet recruiting, and results may not lead to a better treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEDIATRIC GROWTH HORMONE DEFICIENCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
Wuhan, Hubei, 430000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.